Opthea controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C, VEGF-D and VEGF receptor-3 (VEGFR-3).
Our lead molecule is a soluble form of VEGFR-3, OPT-302 (formerly VGX-300), that acts as a VEGF-C/VEGF-D ‘trap’. The molecule blocks blood and lymphatic vessel growth and inhibits vascular leakage. OPT-302 is initially being developed for the treatment of neovascular (‘wet’) age-related macular degeneration (wet AMD), the leading cause of blindness in the Western world, and diabetic macular edema (DME), with the potential to expand our development program for other eye diseases.
Opthea is developing OPT-302 for use in combination with existing VEGF-A inhibitors in patients with wet AMD and DME.
Our strategy is to achieve a more complete blockade of the VEGF family of proteins and more effectively block the abnormal blood vessel growth and vessel leakage that occurs at the back of the eye in people with these eye diseases. By inhibiting these processes, our objective is to improve patients' vision.